Chen Bihua

CIK 000159921413 companiesBOSTON, MA

SEC Profile

Transactions

Companies

Filings

CIK

0001599214

Recent Transactions

50 trades

Sale
EyePoint, Inc.$EYPT
Common Stock
2025-12-04$15.70/sh−60,000→ 8,265,000 total
Purchase
BRIGHT MINDS BIOSCIENCES INC.$DRUG
Common Shares
2024-11-04$21.70/sh+184,331→ 1,059,331 total
Purchase
BRIGHT MINDS BIOSCIENCES INC.$DRUG
Common Shares
2024-10-16$25.22/sh+3,107→ 875,000 total
Purchase
BRIGHT MINDS BIOSCIENCES INC.$DRUG
Common Shares
2024-10-16$23.21/sh+39,743→ 864,743 total
Purchase
BRIGHT MINDS BIOSCIENCES INC.$DRUG
Common Shares
2024-10-16$24.03/sh+7,150→ 871,893 total
Purchase
BRIGHT MINDS BIOSCIENCES INC.$DRUG
Common Shares
2024-10-15$7.31/sh+8,900→ 795,922 total
Purchase
BRIGHT MINDS BIOSCIENCES INC.$DRUG
Common Shares
2024-10-15$9.26/sh+2,700→ 801,222 total
Purchase
BRIGHT MINDS BIOSCIENCES INC.$DRUG
Common Shares
2024-10-15$4.53/sh+238,097→ 690,506 total
Purchase
BRIGHT MINDS BIOSCIENCES INC.$DRUG
Common Shares
2024-10-15$11.72/sh+19,169→ 820,391 total
Purchase
BRIGHT MINDS BIOSCIENCES INC.$DRUG
Common Shares
2024-10-15$8.80/sh+2,600→ 798,522 total
Purchase
BRIGHT MINDS BIOSCIENCES INC.$DRUG
Common Shares
2024-10-15$12.35/sh+4,609→ 825,000 total
Purchase
BRIGHT MINDS BIOSCIENCES INC.$DRUG
Common Shares
2024-10-15$6.42/sh+33,343→ 787,022 total
Purchase
BRIGHT MINDS BIOSCIENCES INC.$DRUG
Common Shares
2024-10-15$5.92/sh+63,173→ 753,679 total
Purchase
BioAge Labs, Inc.$BIOA
Common Stock
2024-09-27$18.00/sh+450,000→ 1,629,529 total
Conversion
BioAge Labs, Inc.$BIOA
Series D Redeemable Convertible Preferred Stock
2024-09-27−5,263,772→ 0 total
Conversion
BioAge Labs, Inc.$BIOA
Common Stock
2024-09-27+1,179,529→ 1,179,529 total
Purchase
Corbus Pharmaceuticals Holdings, Inc.$CRBP
Common Stock
2024-09-20$17.48/sh+45,085→ 2,070,085 total
Purchase
Corbus Pharmaceuticals Holdings, Inc.$CRBP
Common Stock
2024-09-20$22.23/sh+25,769→ 2,375,000 total
Purchase
Corbus Pharmaceuticals Holdings, Inc.$CRBP
Common Stock
2024-09-20$18.36/sh+25,943→ 2,096,028 total
Purchase
Corbus Pharmaceuticals Holdings, Inc.$CRBP
Common Stock
2024-09-20$20.42/sh+139,551→ 2,301,667 total
Purchase
Corbus Pharmaceuticals Holdings, Inc.$CRBP
Common Stock
2024-09-20$19.61/sh+66,088→ 2,162,116 total
Purchase
Corbus Pharmaceuticals Holdings, Inc.$CRBP
Common Stock
2024-09-20$21.47/sh+47,564→ 2,349,231 total
Award
Biomea Fusion, Inc.$BMEA
Stock Option (right to buy)
2024-06-12+51,025→ 51.025 total
Purchase
EyePoint, Inc.$EYPT
Common Stock
2024-05-06$11.70/sh+642,847→ 8,117,847 total
Purchase
EyePoint, Inc.$EYPT
Common Stock
2024-05-06$12.36/sh+207,153→ 8,325,000 total
Purchase
EyePoint, Inc.$EYPT
Common Stock
2024-04-18$17.62/sh+395,244→ 7,288,479 total
Purchase
EyePoint, Inc.$EYPT
Common Stock
2024-04-18$18.90/sh+186,521→ 7,475,000 total
Sale
Immuneering Corp$IMRX
Class A Common Stock
2024-04-01$3.01/sh−10→ 3,294,163 total
Sale
Immuneering Corp$IMRX
Class A Common Stock
2024-04-01$2.90/sh−398,600→ 2,895,273 total
Sale
Immuneering Corp$IMRX
Class A Common Stock
2024-04-01$3.03/sh−600→ 3,294,173 total
Sale
Immuneering Corp$IMRX
Class A Common Stock
2024-04-01$2.97/sh−280→ 3,293,873 total
Sale
Immuneering Corp$IMRX
Class A Common Stock
2024-04-01$2.98/sh−10→ 3,294,153 total
Sale
Immuneering Corp$IMRX
Class A Common Stock
2024-04-01$3.05/sh−100→ 3,294,773 total
Sale
Immuneering Corp$IMRX
Class A Common Stock
2024-04-01$3.07/sh−100→ 3,295,173 total
Sale
Immuneering Corp$IMRX
Class A Common Stock
2024-04-01$3.06/sh−300→ 3,294,873 total
Sale
Immuneering Corp$IMRX
Class A Common Stock
2024-03-15$2.14/sh−400,000→ 3,295,273 total
Sale
Immuneering Corp$IMRX
Class A Common Stock
2024-03-14$5.97/sh−11,040→ 3,695,273 total
Sale
Immuneering Corp$IMRX
Class A Common Stock
2024-03-14$5.37/sh−54,215→ 3,706,313 total
Sale
Immuneering Corp$IMRX
Class A Common Stock
2024-03-14$4.25/sh−98,570→ 3,760,528 total
Sale
Immuneering Corp$IMRX
Class A Common Stock
2024-03-14$3.23/sh−345,266→ 3,859,098 total
Purchase
Corbus Pharmaceuticals Holdings, Inc.$CRBP
Common Stock
2024-03-08$45.26/sh+156,597→ 2,016,138 total
Purchase
Corbus Pharmaceuticals Holdings, Inc.$CRBP
Common Stock
2024-03-08$41.23/sh+29,342→ 1,754,342 total
Purchase
Corbus Pharmaceuticals Holdings, Inc.$CRBP
Common Stock
2024-03-08$44.62/sh+61,668→ 1,859,541 total
Purchase
Corbus Pharmaceuticals Holdings, Inc.$CRBP
Common Stock
2024-03-08$43.26/sh+18,548→ 1,797,873 total
Purchase
Corbus Pharmaceuticals Holdings, Inc.$CRBP
Common Stock
2024-03-08$42.25/sh+24,983→ 1,779,325 total
Purchase
Corbus Pharmaceuticals Holdings, Inc.$CRBP
Common Stock
2024-03-08$45.96/sh+8,862→ 2,025,000 total
Purchase
Corbus Pharmaceuticals Holdings, Inc.$CRBP
Common Stock
2024-03-07$39.13/sh+10,736→ 1,532,535 total
Purchase
Corbus Pharmaceuticals Holdings, Inc.$CRBP
Common Stock
2024-03-07$39.99/sh+90,325→ 1,622,860 total
Purchase
Corbus Pharmaceuticals Holdings, Inc.$CRBP
Common Stock
2024-03-07$37.82/sh+46,799→ 1,521,799 total
Purchase
Corbus Pharmaceuticals Holdings, Inc.$CRBP
Common Stock
2024-03-07$41.23/sh+102,140→ 1,725,000 total

Companies

Recent Filings

Address

C/O CORMORANT ASSET MANAGEMENT, LP 200 CLARENDON STREET, 52ND FLOOR

BOSTON, MA, 02116

View on SEC.gov